๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Function testing of lymphokine-activated killer cells from normal subjects and patients with interleukin-2-dependent immunodeficiency

โœ Scribed by R. V. Petrov; L. V. Koval'chuk; A. R. Kalinina; A. S. Pavlyuk; T. Yu. Ul'yanova

Publisher
Springer US
Year
1989
Tongue
English
Weight
378 KB
Volume
107
Category
Article
ISSN
0007-4888

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase iii randomized trial of interleuki
Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma
โœ Teresa Murray Law; Robert J. Motzer; Madhu Mazumdar; Kenneth W. Sell; Philip Wal ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 723 KB

Background. Treatment with interleukin-2 (IL-2) and lymphokine-activated killer cells (LAK) resulted in responses in some patients with advanced renal cell carcinoma (RCC). However, the relative therapeutic benefit of the addition of LAK to IL-2 was unknown. Methods. A randomized Phase I11 trial wa

Lack of correlation between peripheral b
Lack of correlation between peripheral blood lymphokine-activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2
โœ A. K. Ghosh; H. Dazzi; N. Thatcher; M. Moore ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 634 KB

A phase-1/11 study of recombinant interleukin 2 (rll-2) was performed in 31 melanoma patients. The first dose of rlL-2 was given intrasplenically followed 4 hr later by an i.v. dose and 3 further i.v. doses on alternate days. Three courses of treatment were planned at 3-week intervals. The maximum t